Opinion|Videos|August 28, 2024
Overview of the JUPITER and POLARIS-2 Trials
Victoria M. Villaflor, MD, provides insights on the role of immune checkpoint inhibitors in treating nasopharyngeal carcinoma, focusing on the JUPITER and POLARIS-2 clinical trials.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Have you had clinical experience with immune checkpoint inhibitors in combination with chemotherapy for your patients with NPC?
- Please give your thoughts on the JUPITER and POLARIS-2 trials in NPC.
Advertisement
Related to this article
Izalontamab brengitecan was approved in China for recurrent/metastatic NPC following disease progression on chemotherapy and PD-1/PD-L1 inhibition.
Advertisement
Advertisement
Trending on OncLive
1
SERENA-6 Controversies Push the Breast Cancer Field to Consider the Future Role of ctDNA-Guided Treatment Decisions
2
FDA Approval Positions Belzutifan Plus Pembrolizumab as a New Adjuvant Standard in ccRCC
3
SYNC-T SV-102 Employs Novel Mechanism to Target Immunologically ‘Cold’ Tumors in Advanced Metastatic Prostate Cancer
4
Zanubrutinib Plus R-BAP Elicits High Response Rates in Treatment-Naive Mantle Cell Lymphoma
5